- The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein 11 October 2021 Georgina C Girt
- Variation on a theme: mapping microglial heterogeneity 26 September 2021 Sam J Washer
- A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 23 September 2021 Jiandong Huo
- Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern 18 August 2021 Donal T Skelly
- Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress 31 July 2021 Luiza Mendonça
- Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium 25 June 2021 Alun Vaughan-Jackson
- Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism 28 May 2021 Justyna Okarmus
- Geographical distribution of fertility rates in 70 low-income, lower-middle-income, and upper-middle-income countries, 2010-16: a subnational analysis of cross-sectional surveys 21 May 2021 Carla Pezzulo
- Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism 20 May 2021 Joanne Ng
- Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers 30 April 2021 Björn F Vahsen
Postdoctoral Research Assistant | Janssen Pharmaceutica | email@example.com
Dr. Sharat Warrier is a postdoctoral researched who joined the lab in 2018, to research the role of complement in Alzheimer´s disease.
Alzheimer’s disease (AD) is the most common contributor to dementia. It´s underlying mechanisms are complex, multifactorial, and incompletely understood. It has long been established that neuroinflammation and, more specifically, activation of the complement system, has an important role in pathological processes in AD brains. Complement composed of over 40 interacting proteins, is an ancient and powerful arm of the innate immune system, participating in the recognition, trafficking, elimination of pathogens and misfolded proteins, and maintaining homeostasis. In AD interest over complement stems from the recent large GWA studies which identified >25 genetic risk loci, including several complement associated genes. This is a collaborative industry funded project, jointly supervised by Dr. Sally Cowley at the James Martin Stem Cell Facility, Dr. Elena Di Daniel at the Alzheimer´s Research UK Oxford Drug Discovery Institute and Dr. Louis De Muynck at Janssen pharmaceutica in Belgium. The main goal is to understand the cell type in question for complement expression using iPSC derived cell types of the CNS and the role of the complement proteins in relation to progression of disease.
Sharat graduated with a BSc in Biotechnology where he picked up lab skills with a particular interest in molecular biology techniques. This was followed by a MSc in Industrial and Commercial Biotechnology from Newcastle University in 2009. The research project involved studying and optimising microalgae growth for biofuel production. This was followed by an advanced diploma in Clinical Research and Pharmacovigilance from ICRI, India, to learn and understand the different regulatory processes involved in bringing drugs to market and the downstream safety studies. This was then followed by a PhD at the Ghent University, Belgium with Prof. Petra De Sutter, on understanding the emergence of pluripotency in human embryos and deciphering the role of the different states of pluripotency in human.
His research interests combine stem cell biology, embryology and neuroscience and has been widely published in several peer-reviewed scientific journals. He is passionate about bridging the gap between academia and industry and aims to utilise his analytical, scientific and marketing skill set developed through his education and job experiences to nurture his entrepreneurial and research skill set.